OVID

Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders caused by neuronal hyperexcitability, with a focus on epilepsy and psychiatric conditions. The company's pipeline includes five clinical-stage programs, two of which have advanced to late-stage trials, targeting drug-resistant focal onset seizures, developmental and epileptic encephalopathies including tuberous sclerosis complex seizures and infantile spasms, psychosis associated with Parkinson's disease and Lewy body dementia, and schizophrenia, with several preclinical programs in development for other forms of psychosis and mood disorders.

Pipeline

Catalyst Calendar